Business
NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2024 RESULTS
Fourth quarter total revenue of $18.9 million, up 12% year-over-year Q4 adjusted EBITDA ...
About this update from Neupath Health Inc.
[{"type":"text","content":"NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2024 RESULTS\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwnowrap { white-space: nowrap }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl18 { padding-left: 90px }\n.bwpadl6 { padding-left: 30px }\n.bwpadr0 { padding-right: 0px }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth12 { width: 12% }\n.bwwidth52 { width: 52% }\n.bwwidth76 { width: 76% }\n \n\n\n\n\n\n Fourth quarter total revenue of $18.9 million, up 12% year-over-year\n \n\n\n\n Q4 adjusted EBITDA\n \n (1)\n \n of $0.9 million, up 18% year-over-year, and our 24\n \n th\n \n consecutive quarter of positive adjusted EBITDA. Full year adjusted EBITDA up 19% year-over-year\n \n\n\n\n Positive cash flows, with significant investments in our facilities to support future growth\n \n\n\n\n In Q1 2025 performed the first-ever injection in North America of Arthrosamid\n \n ®\n \n (2.5% iPAAG) at its Mississauga, Ontario clinic\n \n\n\n\n In Q1 2025 secured a new Credit Facility with National Bank to support growth initiatives\n \n\n\n\n\n\n NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months and year ended December 31, 2024. All figures are in Canadian dollars, unless otherwise noted.\n \n\n “We once again delivered strong organic growth while continuing to invest in our facilities,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “These investments, new procedures such as the recently launched Arthrosamid, and our new Credit Facility will accelerate organic and inorganic growth to better serve patients, with more services, in more communities.”\n \n\n\n Financial and Operational ...